BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Core Insights - BriaCell Therapeutics Corp. will present positive biomarker and survival data at the 2025 San Antonio Breast Cancer Symposium, highlighting advancements in cancer immunotherapy [1][6] - The company emphasizes its commitment to improving survival and clinical outcomes for cancer patients with unmet medical needs through its innovative therapies [2] Clinical Data and Presentations - The company will showcase three poster presentations at the symposium, focusing on positive Phase 2 safety and efficacy signals, as well as biomarker findings from both Phase 2 and pivotal Phase 3 studies [6] - The pivotal Phase 3 study of Bria-IMT+CPI is ongoing, with an interim analysis expected in the first half of 2026 [6] - The Bria-IMT regimen has received Fast Track Designation from the US FDA, indicating its potential significance in cancer treatment [6] Leadership Statements - William V. Williams, MD, President & CEO, expressed confidence in the pivotal Phase 3 study in metastatic breast cancer, supported by positive clinical data and biomarker findings [2] - Miguel A. Lopez-Lago, PhD, Chief Scientific Officer, highlighted the importance of biomarker data in understanding the mechanism of action of their novel immunotherapy [2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4]